Annals of Emergency Medicine
Volume 43, Issue 3 , Pages 318-328 , March 2004

Is it influenza or anthrax? A decision analytic approach to the treatment of patients with influenza-like illnesses

  • Andrew M Fine, MD, MPH

      Affiliations

    • Division of Emergency Medicine, Children's Hospital Boston, Harvard Medical School, Boston, MA, USA
    • Corresponding Author InformationAddress for correspondence: Andrew M. Fine, MD, MPH, Division of Emergency Medicine, Children's Hospital Boston, 300 Longwood Avenue, Boston, MA, 02115; 617-355-6624, fax 617-731-3279
    • ,
  • John B Wong, MD

      Affiliations

    • Division of Clinical Decision Making, Tufts–New England Medical Center, Boston, MA, USA
    • ,
  • Hamish S.F Fraser, MBChB, MSc

      Affiliations

    • Informatics Program, Children's Hospital Boston, Harvard Medical School, Boston, MA, USA
    • ,
  • Gary R Fleisher, MD

      Affiliations

    • Division of Emergency Medicine, Children's Hospital Boston, Harvard Medical School, Boston, MA, USA
    • ,
  • Kenneth D Mandl, MD, MPH

      Affiliations

    • Division of Emergency Medicine, Children's Hospital Boston, Harvard Medical School, Boston, MA, USA
    • Informatics Program, Children's Hospital Boston, Harvard Medical School, Boston, MA, USA

Received 14 May 2003 ,Revised 11 September 2003 ,Accepted 17 September 2003.

References 

    References
  1. Centers for Disease Control and Prevention . Notice to readers: evaluation of postexposure antibiotic prophylaxis to prevent anthrax. MMWR Morb Mortal Wkly Rep. 2002;51:59
  2. Shepard CW, Soriano-Gabarro M, Zell ER, et al.  Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis. 2002;8:1124–1132
  3. Centers for Disease Control and Prevention . Notice to readers: considerations for distinguishing influenza-like illness from inhalational anthrax. MMWR Morb Mortal Wkly Rep. 2001;50:984–986
  4. Kuehnert MJ, Doyle TJ, Hill HA, et al.  Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses. Clin Infect Dis. 2003;36:328–336
  5. Inglesby T, O'Toole T, Henderson DA, et al.  Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA. 2002;287:2236–2252
  6. Centers for Disease Control and Prevention . Update: investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR Morb Mortal Wkly Rep. 2001;50:941–948
  7. Swartz MN. Recognition and management of anthrax: an update. N Engl J Med. 2001;345:1621–1626
  8. Shafazand S, Doyle R, Ruoss S, et al.  Inhalational anthrax: epidemiology, diagnosis, and management. Chest. 1999;116:1369–1376
  9. Mayer TA, Bersoff-Matcha S, Murphy C, et al.  Clinical presentation of inhalational anthrax following bioterrorism exposure. JAMA. 2001;286:2549–2553
  10. Inglesby TV, Henderson DA, Bartlett JG, et al.  Anthrax as a biological weapon: medical and public health management: Working Group on Civilian Biodefense [erratum appears in JAMA 2000;283:1963]. JAMA. 1999;281:1735–1745
  11. Dixon TC, Meselson M, Guillemin J, et al.  Anthrax. N Engl J of Med. 1999;341:815–826
  12. Meselson M, Guillemin J, Hugh-Jones M, et al.  The Sverdlovsk anthrax outbreak of 1979. Science. 1994;266:1202–1208
  13. Williams JL, Noviello SS, Griffith KS, et al.  Anthrax postexposure prophylaxis in postal workers, Connecticut, 2001. Emerg Infect Dis. 2002;8:1133–1137
  14. Jefferds MD, Laserson K, Fry AM, et al.  Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, DC, 2001. Emerg Infect Dis. 2002;8:1138–1144
  15. Henretig FM, Cieslak TJ, Kortepeter MG, et al.  Medical management of the suspected victim of bioterrorism: an algorithmic approach to the undifferentiated patient. Emerg Med Clin North Am. 2002;20:351–364
  16. Jernigan JA, Stephens DS, Ashford DA, et al.  Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis. 2001;7:933–944
  17. Bell DM, Kozarsky PE, Stephens DS. Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg Infect Dis. 2002;8:222–225
  18. Stolberg SG. For anthrax survivors, a halting painful recovery. New York Times. May 7, 2002;Section F:1
  19. Monto AS, Gravenstein S, Elliott M, et al.  Clinical signs and symptoms predicting influenza infection. Arch Intern Med. 2000;160:3243–3247
  20. Covalciuc K, Webb K, Carlson C. Comparison of four clinical specimen types for detection of influenza A and B viruses by optical immunoassay (FLU OIA Test) and cell culture methods. J Clin Microbiol. 1999;37:3971–3974
  21. Uyeki TM. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza. Pediatr Infect Dis. 2003;22:164–177
  22. National Center for Health Statistics. Fast Stats: Influenza. Available at: http://www.cdc.gov/nchs/fastats/flu.htm. Accessed April 25, 2003.
  23. Williams AA, Parashar UD, Stoica A, et al.  Bioterrorism-related anthrax surveillance, Connecticut, September-December, 2001. Emerg Infect Dis. 2002;8:1078–1082
  24. Medical Economics Staff . Physicians' Desk Reference. 56th ed.. Montvale, NJ: Medical Economics Company; 2002;
  25. Centers for Disease Control and Prevention . Update: investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis. MMWR Mortal Wkly Rep. 2001;50:973–976
  26. Dietz BL. The fluoroquinolones. Clin Toxicol Rev. 1997;20:1–2
  27. Centers for Disease Control and Prevention . Update: adverse events associated with anthrax prophylaxis among postal employees: New Jersey, New York City, and the District of Columbia Metropolitan Area, 2001. MMWR Morb Mortal Wkly Rep. 2001;50:1051–1054
  28. Segev S, Yaniv I, Haverstock D, et al.  Safety of long-term therapy with ciprofloxacin: data analysis of controlled clinical trials and review. Clin Infect Dis. 1999;28:299–308
  29. Davis H, McGoodwin E, Reed TG. Anaphylactoid reactions reported after treatment with ciprofloxacin. Ann Intern Med. 1989;111:1041–1043
  30. Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med. 2001;161:15–21
  31. Yocum MW, Butterfield JH, Klein JS, et al.  Epidemiology of anaphylaxis in Olmsted County: a population-based study. J Allergy Clin Immunol. 1999;104(2 pt 1):452–456
  32. Kaplan RM, Bush JW, Berry CC. Health status index: category rating versus magnitude estimation for measuring levels of well-being. Med Care. 1979;17:501–525
  33. Hupert N, Bearman GML, Mushlin AI, et al.  Accuracy of screening for inhalational anthrax after a bioterrorist attack. Ann Intern Med. 2003;139(5 part 1):337–345
  34. Sox HC. A triage algorithm for inhalational anthrax. Ann Intern Med. 2003;139(5 part 1):379–381
  35. Sackett D, Haynes R, Tugwell P, et al.  Clinical Epidemiology: A Basic Science for Clinical Medicine. 2nd ed.. Philadelphia, PA: Lippincott Williams & Wilkins; 1991;
  36. Schapira MM, Matchar DB, Young MJ. The effectiveness of ovarian cancer screening: a decision analysis model. Ann Intern Med. 1993;118:838–843
  37. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions: standardizing data on outcomes. N Engl J Med. 1998;339:380–386
  38. Wein LM, Craft DL, Kaplan EH. Emergency response to an anthrax attack. Proc Natl Acad Sci USA. 2003;100:4346–4351
  39. Sacchi CT, Whitney AM, Mayer LW, et al.  Sequencing of 16S rRNA gene: a rapid tool for identification of Bacillus anthracis. Emerg Infect Dis. 2002;8:1117–1123
  40. Quinn CP, Semenova VA, Elie CM, et al.  Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis. 2002;8:1103–1110
  41. De BK, Bragg SL, Sanden GN, et al.  A two-component direct fluorescent-antibody assay for rapid identification of Bacillus anthracis. Emerg Infect Dis. 2002;8:1060–1065
  42. Lober WB, Karras BT, Wagner MM, et al.  Roundtable on bioterrorism detection: information system-based surveillance. J Am Med Inform Assoc. 2002;9:105–115

☆ Author contributions: AMF, HSFF, and KDM conceived the study. AMF, JBW, HSFF, GRF, and KDM designed the methods. JBW provided statistical advice and expertise on modeling outcomes in the decision analysis. GRF provided expert infectious disease advice. AMF drafted the manuscript, and all authors contributed substantially to its revision. AMF takes responsibility for the paper as a whole.Presented in part at the Society for Pediatric Research, Baltimore, MD, May 2002.Supported in part by National Research Service Award grant T32 HD40128-01 (Research Training in Pediatric Emergency Medicine); by the National Institutes of Health through grants R01LM07677-01 and LM07092-10 from the National Library of Medicine, Bethesda, MD; and by contract 290-00-0020 from the Agency for Healthcare Research and Quality, Rockville, MD.Reprints not available from the authors.

PII: S0196-0644(03)00968-5

doi: 10.1016/j.annemergmed.2003.09.007

Annals of Emergency Medicine
Volume 43, Issue 3 , Pages 318-328 , March 2004

Article Tools

* Image Usage & Resolution